Pricing Log in Create free account
Sunday 18 October 2026 Export FHTX’s income statement to Excel — free account

Foghorn Therapeutics Inc.

FHTX Healthcare Biotechnology

Foghorn Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 36.8% from fiscal 2024. In the quarter to June 2026, revenue grew 112.7%, EPS grew 64.3% and free cash flow grew 14.9%, each against the same quarter a year earlier.

1.85 0.04 −2.12%
Market cap
$112.2M
P/E
0.0×
Fwd P/E
−3.7×
Dividend yield
—
F-score
2/9
Altman Z
−4.46
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Foghorn Therapeutics Inc. (FHTX) Business Profile

Updated before January 2025

Company Overview

Foghorn Therapeutics Inc. (FHTX) is a cutting-edge biotechnology company that focuses on developing innovative therapies targeting the chromatin regulatory system. Founded in 2015, the company is headquartered in Cambridge, Massachusetts, a hub for biotech innovation. Foghorn was co-founded by Dr. Cigall Kadoch, a leading expert in chromatin biology, and Dr. Gerald Crabtree, a renowned scientist in the field of gene regulation. The company operates under the leadership of Adrian Gottschalk, who serves as the President and Chief Executive Officer. Foghorn’s mission is to pioneer a new class of medicines by leveraging its proprietary Gene Traffic Control® platform to address diseases driven by dysregulation of the chromatin regulatory system, including cancer and other serious conditions.

Core Business Segments

Foghorn Therapeutics operates primarily in the field of precision medicine, with a focus on the following core business segments:

1. Chromatin Regulatory System Therapeutics

Foghorn’s primary focus is on developing therapies that target the chromatin regulatory system, which plays a critical role in gene expression and cellular function. The company’s proprietary Gene Traffic Control® platform enables the identification and development of small molecules and protein degraders to modulate chromatin regulatory proteins. Key products and programs include:

  • BRG1/BRM Program: Targeting the BRG1 and BRM proteins, which are implicated in various cancers, including non-small cell lung cancer (NSCLC) and ovarian cancer.
  • ARID1A/ARID1B Program: Focused on developing therapies for cancers with mutations in ARID1A or ARID1B, such as ovarian and endometrial cancers.
  • Selective Protein Degraders: Leveraging the Gene Traffic Control® platform to develop targeted protein degraders for chromatin regulatory proteins.

2. Oncology Therapeutics

Foghorn is actively developing a pipeline of oncology therapies aimed at addressing unmet medical needs in cancer treatment. The company’s approach involves targeting specific genetic and epigenetic drivers of cancer to develop precision therapies.

3. Collaborative Partnerships

Foghorn collaborates with leading pharmaceutical companies to advance its research and development efforts. Notable partnerships include collaborations with Merck and Loxo Oncology (a subsidiary of Eli Lilly) to co-develop therapies targeting chromatin regulatory proteins.

Business Model

Foghorn Therapeutics operates on a research-driven business model that integrates its proprietary Gene Traffic Control® platform with a robust pipeline of therapeutic candidates. The company generates revenue through:

  • Collaborative Agreements: Foghorn partners with pharmaceutical companies to co-develop therapies, receiving milestone payments, research funding, and royalties on commercialized products.
  • Licensing: The company licenses its proprietary technologies and intellectual property to partners, creating additional revenue streams.
  • Product Development: Foghorn invests heavily in the development of its own therapeutic candidates, with the goal of bringing innovative medicines to market.

Strategic Direction

Foghorn Therapeutics is committed to advancing its pipeline of precision therapies and expanding its Gene Traffic Control® platform. Key strategic priorities include:

  • Pipeline Expansion: Foghorn aims to broaden its therapeutic pipeline by targeting additional chromatin regulatory proteins and exploring new indications beyond oncology.
  • Global Reach: The company plans to expand its presence in international markets, leveraging partnerships and collaborations to accelerate global development and commercialization.
  • Sustainability Goals: Foghorn is dedicated to sustainable practices in its research and development activities, including minimizing environmental impact and promoting ethical standards in clinical trials.
  • Innovation: The company continues to invest in cutting-edge technologies and research to maintain its leadership position in the field of chromatin biology.

Competitive Landscape

Foghorn Therapeutics operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Epizyme, Inc.: Focused on developing epigenetic therapies for cancer and other diseases.
  • Constellation Pharmaceuticals: Specializes in targeting epigenetic regulators for oncology and immuno-oncology indications.
  • Syros Pharmaceuticals: Develops therapies targeting gene expression and chromatin biology.
  • Big Pharma Companies: Large pharmaceutical companies such as Pfizer, Novartis, and Roche are also investing in precision medicine and epigenetic therapies, posing indirect competition.

Risk Factors

Foghorn Therapeutics faces several risks that could impact its business operations and financial performance:

  • Regulatory Challenges: The development and approval of new therapies are subject to stringent regulatory requirements, which can delay or prevent product commercialization.
  • Market Dependence: The company’s success depends on the commercial viability of its therapeutic candidates, which are still in various stages of development.
  • Supply Chain Disruptions: Foghorn relies on third-party suppliers and manufacturers for critical components, making it vulnerable to supply chain disruptions.
  • Competition: Intense competition in the biotechnology sector could impact Foghorn’s market share and pricing power.
  • Financial Risks: As a clinical-stage company, Foghorn may face challenges in securing sufficient funding to support its research and development activities.

Recent Developments

Foghorn Therapeutics has made significant progress in advancing its pipeline and corporate strategy. Recent developments include:

  • Clinical Trials: The company has initiated multiple clinical trials for its lead programs, including the BRG1/BRM and ARID1A/ARID1B programs.
  • Partnership with Merck: Foghorn expanded its collaboration with Merck to include additional targets within the chromatin regulatory system.
  • IPO: Foghorn successfully completed its initial public offering (IPO) in 2020, raising capital to support its research and development efforts.
  • COVID-19 Impact: The company has implemented measures to mitigate the impact of the COVID-19 pandemic on its operations, including remote work policies and adjustments to clinical trial timelines.

Investment Considerations

Investors considering Foghorn Therapeutics should weigh the following strengths and risks:

Strengths

  • Innovative Platform: The Gene Traffic Control® platform positions Foghorn as a leader in chromatin biology and precision medicine.
  • Strong Pipeline: The company has a robust pipeline of therapeutic candidates targeting high-value indications.
  • Collaborative Partnerships: Strategic collaborations with industry leaders provide validation and financial support for Foghorn’s programs.
  • Experienced Leadership: Foghorn’s management team brings extensive expertise in biotechnology and drug development.

Risks

  • Early-Stage Company: As a clinical-stage company, Foghorn has yet to commercialize any products, making it a high-risk investment.
  • Regulatory and Clinical Risks: The success of Foghorn’s programs depends on favorable clinical trial outcomes and regulatory approvals.
  • Market Competition: The biotechnology sector is highly competitive, with numerous companies targeting similar indications.

Conclusion

Foghorn Therapeutics Inc. is at the forefront of innovation in the field of chromatin biology, leveraging its proprietary Gene Traffic Control® platform to develop precision therapies for cancer and other diseases. While the company faces significant risks as a clinical-stage biotech, its strong pipeline, strategic partnerships, and experienced leadership position it for long-term growth. As Foghorn continues to advance its programs and expand its platform, it has the potential to make a meaningful impact on the lives of patients and deliver value to investors.